Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Embeda

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Abstract Objective: To review the effects of naltrexone on withdrawal-related adverse events (AEs) and euphoria-related effects… Expand
2014
2014
FDA has approved an updated labeling of morphine sulfate/naltrexone hydrochloride (Embeda, Pfizer) extended release capsules, CII… Expand
Review
2012
Review
2012
BACKGROUND EMBEDA@ (morphine sulfate and naltrexone hydrochloride) extended-release capsules, indicated for management of chronic… Expand
2012
2012
Johnson FK, Ciric S, Boudriau S, et al., Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone… Expand
Review
2012
Review
2012
During the last 2 decades, there has been a dramatic increase in the use of strong opioids for chronic non-cancer pain. This… Expand
2011
2011
Morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA®, King Pharmaceuticals®, Inc., Bristol, TN… Expand
Review
2010
Review
2010
BACKGROUND The introduction of newly formulated extended release (ER) morphine with sequestered naltrexone (Embeda) has provided… Expand
Review
2010
Review
2010
Chronic opioids are often used in the management of chronic osteoarthritis pain. Embeda™ (Alpharma Pharmaceuticals, NJ, USA) is a… Expand
Review
2010
Review
2010
  • The Medical letter on drugs and therapeutics
  • 2010
  • Corpus ID: 28753763